The skin is the body’s largest organ and has many vital functions, such as protection from microbes and the elements. Diseases of the skin are found in all age groups and include many different conditions.
Some of the most common skin diseases are eczema, psoriasis, acne and skin cancer. Several of Meda’s biggest products are in the dermatology therapy area.
Aldara has three indications: actinic keratosis, superficial basal cell carcinomas,and external genital warts in men and women. The active ingredient in Aldara is imiquimod, a proprietary ingredient with a unique action mechanism. Imiquimod is an immunomodulating agent that activates the body's own immune defenses through the skin.
Elidel is a proprietary drug for the treatment of atopic eczema based on pimecrolimus. Atopic eczema is a chronic, recurring inflammatory skin disease. The skin has a barrier function that plays a key role in defense against atopic eczema flare-ups.
Elidel is the first topical preparation developed for the treatment of atopic eczema that does not contain a corticosteroid. Elidel has been documented in studies involving more than 60,000 patients. Elidel is currently available for sale in 90 markets around the world, through Meda’s own marketing organization and through partners. In North America, Elidel is out-licensed to Valeant, who will also partner with Meda for product development related to Elidel.
Zyclara is used to treat actinic keratosis which is a common type of cancer affecting an increasing share of the population. The active ingredient in Zyclara is imiquimod 3.75%, a formulation that allows Zyclara to be used on a significantly larger treatment area. Zyclara was approved in Europe in 2012 and was launched in 2013.